Clinical trial
In Vitro Evaluation Of Allergic Reactions In Hemophilia B Subjects Who Have Exhibited A Systemic Allergic Response After Exposure To BeneFIX (Nonacog Alfa; Recombinant Factor IX)
NCT00244114 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- In Vitro Evaluation Of Allergic Reactions In Hemophilia B Subjects Who Have Exhibited A Systemic Allergic Response After Exposure To BeneFIX (Nonacog Alfa; Recombinant Factor IX)
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 28, 2006
- Completion date
- December 31, 2009
- Enrollment
- 20 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.